Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon and Ribavirin in HCV with/without Renal Disease
NCT00028093Phase 4Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Dec 2001
- Primary completion
- Jun 2010
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2a and ribavirin in hepatitis C (HCV) (4 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoints: Sustained Virologic Response at 18 months and Change in Hepatitis C Virus RNA Levels During Phase I. Started Dec 2001; status: completed.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00028093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00028093.